Graves’ Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019

Feb. 24, 2012 - PRLog -- GlobalData estimates that the global (the US, the UK, Germany, France, Italy, Spain and Japan) Graves’
disease therapeutics market was worth $169.1m in 2011, expects it to grow at a Compound Annual Growth Rate (CAGR) of 0.9% for the next eight years, to reach $182m by 2019. This very slow growth forecast is primarily attributed to the weak pipeline, coupled with the market being well served by generics. The incidence rate of Graves’ disease is static; therefore only the growing population is contributing to the growth of the market.

GlobalData estimates that the prevailing market landscape is strong, with generic antithyroid agents and
RAI therapy expected to continue to dominate the market during the forecast period. These products offer high efficacy and safety to Graves’ disease patients; as a result, unmet need in the market is low, providing little potential for pipeline drugs to capture market share unless they are disease-modifying in
nature and aim at treating the underlying autoimmune condition. However, as the pipeline contains only one disease-modifying drug for Graves’ disease, in the discovery stage of development, the market will continue to be dominated by the existing generic drugs.

The weak pipeline indicates a lack of research in the Graves’ disease therapeutics area. Pharmaceutical
companies, research institutes and universities are reluctant to conduct trials in this disease area. As the
market is well-served by the currently marketed products the unmet need in the market is low, which indicates a limited scope of revenue generation by any new drugs treating the condition. However, considering the autoimmune nature of the disease, research into developing immunomodulators for the
prevention of Graves’ disease in high-risk individuals or for the treatment of Graves’ disease may lead to
novel drugs that could change the way the disease is managed

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/RequestSamplePages....


GlobalData, the industry analysis specialist, has released its new report, “Graves’ DiseaeTherapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global graves disease market. The report identifies the key trends shaping and driving the global Graves’ disease market and provides insight into the current competitive landscape and emerging companies expected to significantly alter the positions of current market leaders. Most importantly, the report provides valuable insights on pipeline products within the global Graves’ disease market. This report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/ReportStore/Report.aspx?ID=Peri...


Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.